Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus

Antiviral Research

Volumn 91, Issue 2, 2011, Pages 89-93

  Ölschläger, Stephan ^a   Neyts, Johan ^b   Günther, Stephan ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Arenavirus; Ebola virus; Inosine monophosphate dehydrogenase; Lassa virus; Mopeia virus; Ribavirin

Indexed keywords

5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; ANTIVIRUS AGENT; GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; RIBAVIRIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARENAVIRUS; ARTICLE; DRUG EFFECT; DRUG MECHANISM; EBOLA VIRUS; ENZYME INHIBITION; IN VITRO STUDY; LASSA FEVER; LASSA VIRUS; MOPEIA VIRUS; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERO CELL; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; EBOLAVIRUS; GUANOSINE; GUANOSINE TRIPHOSPHATE; IMP DEHYDROGENASE; LASSA VIRUS; MYCOPHENOLIC ACID; RIBAVIRIN; RIBONUCLEOSIDES; VERO CELLS; VIRUS REPLICATION;

ARENAVIRUS; EBOLA VIRUS; LASSA VIRUS; MOPEIA VIRUS; ZAIRE EBOLAVIRUS;

EID: 79958281626     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.05.006     Document Type: Article

References (24)

1. Ando K., Suzuki S., Tamura G., Arima K. Antiviral activity of mycophenolic acid. Studies on antiviral and antitumor antibiotics. IV. J. Antibiot. (Tokyo). 1968, 21:649-652.
2. Asper M., Sternsdorf T., Hass M., Drosten C., Rhode A., Schmitz H., Günther S. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J. Virol. 2004, 78:3162-3169.
3. Balzarini J., Karlsson A., Wang L., Bohman C., Horská K., Votruba I., Fridland A., Van Aerschot A., Herdewijn P., De Clercq E. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J. Biol. Chem. 1993, 268:24591-24598.
4. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000, 6:1375-1379.
5. De Clercq E., Cools M., Balzarini J., Snoeck R., Andrei G., Hosoya M., Shigeta S., Ueda T., Minakawa N., Matsuda A. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 1991, 35:679-684.
6. Eriksson B., Helgstrand E., Johansson N.G., Larsson A., Misiorny A., Norén J.O., Philipson L., Stenberg K., Stening G., Stridh S., Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 1977, 11:946-951.
7. Fernandez-Larsson R., O'Connell K., Koumans E., Patterson J.L. Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Antimicrob. Agents Chemother. 1989, 33:1668-1673.
8. Franklin T.J., Cook J.M. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem. J. 1969, 113:515-524.
9. Goswami B.B., Borek E., Sharma O.K., Fujitaki J., Smith R.A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 1979, 89:830-836.
10. Günther S., Asper M., Röser C., Luna L.K., Drosten C., Becker-Ziaja B., Borowski P., Chen H.M., Hosmane R.S. Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro. Antiviral Res. 2004, 63:209-215.
11. Lelke M., Brunotte L., Busch C., Günther S. An N-terminal region of Lassa virus L protein plays a critical role in transcription but not replication of the virus genome. J. Virol. 2010, 84:1934-1944.
12. Leyssen P., Balzarini J., De Clercq E., Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 2005, 79:1943-1947.
13. Leyssen P., De Clercq E., Neyts J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol. Pharmacol. 2006, 69:1461-1467.
14. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314:20-26.
15. McCormick J.B., Webb P.A., Krebs J.W., Johnson K.M., Smith E.S. A prospective study of the epidemiology and ecology of Lassa fever. J. Infect. Dis. 1987, 155:437-444.
16. Morin B., Coutard B., Lelke M., Ferron F., Kerber R., Jamal S., Frangeul A., Baronti C., Charrel R., de Lamballerie X., Vonrhein C., Lescar J., Bricogne G., Günther S., Canard B. The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. PLoS Pathog 2010, 6:e1001038.
17. Ölschläger S., Lelke M., Emmerich P., Panning M., Drosten C., Hass M., Asogun D., Ehichioya D., Omilabu S., Günther S. Improved detection of Lassa virus by reverse transcription-PCR targeting the 5′ region of S RNA. J. Clin. Microbiol. 2010, 48:2009-2013.
18. Panning, M., Laue, T., Ölschläger, S., Eickmann, M., Becker, S., Raith, S., Courbot, M.C., Nilsson, M., Gopal, R., Lundkvist, A., Caro, A., Brown, D., Meyer, H., Lloyd, G., Kümmerer, B.M., Günther, S., Drosten, C., 2007. Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories. J. Infect. Dis. 196(Suppl. 2), S199-S204.
19. Ruiz-Jarabo C.M., Ly C., Domingo E., de la Torre J.C. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 2003, 308:37-47.
20. Severson W.E., Schmaljohn C.S., Javadian A., Jonsson C.B. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 2003, 77:481-488.
21. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., Robins R.K. Broad-spectrum antiviral activity of Virazole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972, 177:705-706.
22. Smee D.F., Bray M., Huggins J.W. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir. Chem. Chemother. 2001, 12:327-335.
23. Streeter D.G., Witkowski J.T., Khare G.P., Sidwell R.W., Bauer R.J., Robins R.K., Simon L.N. Mechanism of action of 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U S A 1973, 70:1174-1178.
24. Sun Y., Chung D.H., Chu Y.K., Jonsson C.B., Parker W.B. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5′-triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob. Agents Chemother. 2007, 51:84-88.